Broadfin Capital’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Broadfin Capital’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-729,301	Closed	-$897K	–	52
2019 Q1	$897K	Sell	729,301 -500,000	-41%	-$569K	0.19%	43
2018 Q4	$1.03M	Sell	1,229,301 -719,253	-37%	-$812K	0.14%	49
2018 Q3	$5.77M	Hold	1,948,554	–	–	0.85%	34
2018 Q2	$7.17M	Hold	1,948,554	–	–	1.13%	28
2018 Q1	$6.82M	Hold	1,948,554	–	–	1.06%	27
2017 Q4	$6.08M	Hold	1,948,554	–	–	0.99%	25
2017 Q3	$13.7M	Hold	1,948,554	–	–	2.03%	17
2017 Q2	$18M	Hold	1,948,554	–	–	2.18%	15
2017 Q1	$20.9M	Hold	1,948,554	–	–	2.53%	13
2016 Q4	$16.4M	Buy	+1,948,554	New	+$17.3M	1.82%	16

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Broadfin Capital's NVLN Position: Q2 2019 in Review

Broadfin Capital sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2019, closing a stake of 729,301 shares — an estimated $897K sold.

Broadfin Capital first reported a position in NVLN in Q4 2016 and held it in 10 quarters. The position peaked at $20.9M in Q1 2017. 35 funds tracked by Wall St. Rank hold NVLN as of Q2 2019.

Broadfin Capital reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2019 after selling out during the quarter.
Broadfin Capital sold 729,301 Novelion Therapeutics Inc. Common Shares shares in Q2 2019, an estimated $897K.
Broadfin Capital first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 10 quarters.
Broadfin Capital's Novelion Therapeutics Inc. Common Shares position peaked at $20.9M in Q1 2017.
35 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2019.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.